Icosavax, Inc.

Deal volume was down last year both in M&A and alliances, but valuations rose. Early in 2023, Pfizer Inc. set the tone for a year of moving on from the COVID-19 pandemic by agreeing to pay $43bn for

Merger and acquisition activity in Q4 2023 flipped the script after a sluggish third quarter, with 10 transactions valued at $1bn or more and two valued above $10bn, according to data recorded by Eval

Hats off to Icosavax, Inc. – $838m isn’t a bad payday for a company with a single clinical-stage candidate. The vaccine maker has been snapped up by AstraZeneca PLC , and the sizeable upfront payme

The American Society of Clinical Oncology annual meeting often is followed by several follow-on public offerings (FOPOs) by small- to mid-sized public biotech companies reporting positive data at the